Status:
COMPLETED
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Central Nervous System Neoplasms
Head and Neck Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
Detailed Description
* To determine the maximum tolerated dose (MTD) of EPO906 administered in combination with radiation therapy and establish a recommend phase II dose. * To evaluate the safety and toxicity profile of E...
Eligibility Criteria
Inclusion
- Requires a minimum of 3 weeks of radiation therapy
- Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy
- World Health Organization (WHO) performance status equal to or less than 2
- Life expectancy equal to or greater than 3 months
Exclusion
- Any peripheral neuropathy
- Unresolved diarrhea greater than grade 1
- Patients who received any other investigational compound within the past 28 days
- Severe cardiac insufficiency
- Patients on Coumadin
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00328458
Start Date
February 1 2004
End Date
July 1 2009
Last Update
May 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107